MacroGenics MGNX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
MacroGenics (MGNX) Core Market Data and Business Metrics
Latest Closing Price
$1.22Price-Earnings Ratio
-1.14Total Outstanding Shares
63.09 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
9704 Medical Center Drive, Rockville, MD, 20850
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 480,805 Shares | 10.34 | 3/14/2025 | 4,972,906 Shares |
| 640,124 Shares | 7.98 | 2/28/2025 | 5,109,250 Shares |
| 735,042 Shares | 7.51 | 2/14/2025 | 5,523,754 Shares |
| 711,105 Shares | 7.64 | 1/31/2025 | 5,435,015 Shares |
| 499,098 Shares | 10.57 | 1/15/2025 | 5,277,634 Shares |
| 462,189 Shares | 11.22 | 12/31/2024 | 5,184,674 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $149.30 Million |
| Net Cash Flow From Operating Activities, Continuing | $-68.37 Million |
| Net Cash Flow From Operating Activities | $-68.37 Million |
| Net Cash Flow From Financing Activities, Continuing | $960,000 |
| Net Cash Flow | $81.88 Million |
| Net Cash Flow, Continuing | $81.88 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $259.69 Million |
| Revenues | $149.96 Million |
| Basic Average Shares | $62.62 Million |
| Basic Earnings Per Share | $-1.07 |
| Net Income/Loss Attributable To Parent | $-66.97 Million |
| Income/Loss From Continuing Operations After Tax | $-66.97 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-66.96 Million |
| Other Comprehensive Income/Loss | $-66.96 Million |
| Comprehensive Income/Loss Attributable To Parent | $-66.96 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $116.06 Million |
| Other Current Assets | $205.98 Million |
| Prepaid Expenses | $11.51 Million |
| Other Current Liabilities | $50.52 Million |
| Fixed Assets | $18.10 Million |
| Liabilities And Equity | $261.65 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||